Orphan CNS therapy developer Minoryx Therapeutics closed a $54.8m series C and MIT's The Engine co-led a $10.5m seed round for Foundation Alloy.
Minoryx Therapeutics, a Spain-based developer of treatments for orphan central nervous system disorders, completed a €51m ($54.8m) series C round yesterday that included an undisclosed amount of debt. The round was co-led by Columbus Venture Partners and Caixa Capital Risc, while CDTI, Fund+, Ysios Capital and other unnamed backers also took part. Minoryx was co-founded by Joan Aymamí, a researcher at Universitat Politècnica de Catalunya, and also exploits research undertaken at University of Barcelona by chief executive Marc Martinell. Minoryx’s shareholders also include Kurma Partners, Idinvest Partners and corporate venturing funds Roche Venture Fund and Chiesi Ventures, as well as SFPI-FPIM, SRIW and Sambrinvest.
Foundation Alloy, a US-based vertically integrated metal part production platform, raised a $10.5m seed round co-led by The Engine, the venture capital firm spun out of Massachusetts Institute of Technology, and Material Impact yesterday. The round included participation by Safar Partners. Foundation Alloy is exploiting research from Massachusetts Institute of Technology and University of California, Irvine.
